2017
Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.
Jalali A, Wang J, Lee W, Zhang J, Wu C, Gibbons D, Tang X, Kalhor N, Izzo J, Behrens C, Fossella F, Tsao A, Lee J, Swisher S, Heymach J, Futreal A, Wistuba I, Herbst R, Papadimitrakopoulou V, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. Journal Of Clinical Oncology 2017, 35: 8538-8538. DOI: 10.1200/jco.2017.35.15_suppl.8538.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune infiltration scoreTumor immune infiltrationCell lung cancerImmune infiltrationLung cancerImmune responseAdvanced non-small cell lung cancerStage I/II diseaseTumor progressionStage I/IIStage III/IVInfiltration of tumorsInflammatory cell countsHigher median survivalLung Cancer ProjectPrimary tumor specimensLung adenocarcinoma samplesTypes of cancerMeans of CD3Tumor coreEstimate packageMedian survivalNSCLC patientsClinical outcomes
2001
Lung cancer in patients under age 40
Skarin A, Herbst R, Leong T, Bailey A, Sugarbaker D. Lung cancer in patients under age 40. Lung Cancer 2001, 32: 255-264. PMID: 11390007, DOI: 10.1016/s0169-5002(00)00233-6.Peer-Reviewed Original ResearchConceptsStage IV diseaseSmall cell carcinomaSquamous cell carcinomaCell carcinomaPerformance statusStage IIIBStage IIIAOlder patientsLung cancerYear survivalAge 40Stage I/IIDana-Farber Cancer InstituteGreater body weight lossWeight lossECOG performance statusPercent of patientsPoor performance statusDuration of symptomsSite of metastasisOverall patient survivalStage of diseaseBody weight lossAbsence of symptomsPercentage of women